Scott & White Healthcare pathologist is co-investigator on breast cancer study

	Tweet

In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells. The most common type of breast cancer is “estrogen-receptor positive” breast cancer.

Velusamy Rangasamy and Ajay Rana, Ph.D., are also the lead authors on the study and are based at Loyola University Medical Center in Chicago where Dr. Rana is a professor of pharmacology.

“What we know is that not all breast tumors are the same and if a tumor is estrogen-receptor positive, it’s possible that chemotherapy isn’t going to be as effective as it could be,” said Dr. Rao. “This is why we see some breast cancer patients on chemo that isn’t working like it should. With this additional information regarding estrogen, it could help us create more targeted therapies in the future.”

"These findings are important because efficiently killing estrogen receptor positive (ER+) breast cancer cells with currently available chemotherapy is a challenging task and many times these ER+ breast tumors don’t respond to classical chemotherapy,” said Dr. Rana. “Our research identified an alternative cellular protein which can serve as a viable target for ER+ breast cancer treatment.”

Dr. Rao went on to say that “with this research we found that in order to make cancer drugs work better, we may need to give patients a different drug and this could possibly shorten the duration of their chemotherapy course if we knew more.”

“Our work suggests that any drugs/agents that will activate this protein will sensitize the ER+ breast cancer cells toward commonly used chemotherapies. We have been working to find the drugs/agents that can activate this protein and kill the ER+ cancer cells,” said Dr. Rana.

Dr. Rana explained that “these findings are encouraging but further research is needed to find how this cellular pathway could be utilized to target estrogen positive breast cancer cells.”

###

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare

RELATED STORIES:
New Technique Detects Early Metastasis of Breast Cancer   Taking tamoxifen to prevent breast cancer can save lives and money   Obesity common in women at risk of breast cancer   Size of Family Could Affect Predicting Breast Cancer Risk   FDA Broadens Clearance For Agendia’s MammaPrint(R)   Tau Protein Expression Predicts Breast Cancer Survival- Though Not as Expected   Breast cancer patients wrongly given the all-clear   Most women would accept more mammograms   Study Finds Diet and Alcohol Alter Epigenetics of Breast Cancer and Could Predict Severity of Diseas   Triple Negative Breast Cancer Targeted in Clinical Trial   Breast cancer treatments impact work status   Breast cancer treatment offers better outcome to women with implants   Study Links Nicotine with Breast Cancer Growth and Spread   Linchpin Gene May Be Useful Target For Breast Cancer Therapies   Lack of social interaction affects health outcomes of breast cancer   Most breast cancers not linked to ovarian cancer   Breast-feeding debate heats up in Massachusetts   High-risk women reluctant to take tamoxifen to prevent breast cancer   High Levels of Estrogen Associated with Breast Cancer Recurrence   Red Or White Wine? Both Are Equal in Terms of Breast-Cancer Risk   Avastin helps breast cancer patients: study   Fertility procedures need not delay breast cancer treatment for younger women

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]